Effect of homocysteinylation of human high-density lipoproteins: A correlation with paraoxonase activity

Metabolism: Clinical and Experimental

Volumn 52, Issue 2, 2003, Pages 146-151

  Ferretti, G ^a   Bacchetti, Tiziana ^a   Marotti, E ^a   Curatola, G ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE THIOLACTONE; LIPID; LIPOPROTEIN; THIOL DERIVATIVE;

ADULT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; HUMAN; LIPID BLOOD LEVEL; MALE; NORMAL HUMAN; OXIDATIVE STRESS; PLASMA; PRIORITY JOURNAL; PROTECTION; PROTEIN ISOLATION; RELIABILITY; TIME; TOXICITY;

EID: 0037304124     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2003.50033     Document Type: Article

References (39)

1. McCully KS: Homocysteine and vascular disease. Nat Med 2:386-389, 1996
2. McCully KS, Wilson RB: Homocysteine theory of arteriosclerosis. Atherosclerosis 22:215-227, 1975
3. Heinecke JW, Kawamura M, Suzuki L, et al: Oxidation of low density lipoprotein by thiol: Superoxide-dependent and -independent mechanisms. J Lipid Res 34:2051-2061, 1993
4. Starkebaum G, Harlan JM: Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 77:1370-1376, 1986
5. Epstein FH: Homocysteine and atherothrombosis. N Engl J Med 338:1042-1050, 1998
6. Jakubowski H: Metabolism of homocysteine-thiolactone in human cell culture: Possible mechanism for pathological consequences of elevated homocysteine levels. J Biol Chem 272:1935-1942, 1997
7. Jakubowski H: Homocysteine thiolactone: Metabolic origin and protein homocysteinylation in humans. J Nutr 130:377S-381S, 2000 (suppl 2)
8. Harker LA, Ross R, Slichter SJ, et al: Homocysteine-induced arteriosclerosis. The role of endothelial cell injury and platelet response to its genesis. J Clin Invest 58:731-741, 1976
9. Gaggi R, Gianni AM: The role of homocysteine in the pathogenesis of arteriosclerosis. Proc First Cong Hung Pharmacol Soc 297, 1973
10. Mercie P, Garnier O, Lascoste L, et al: Homocysteine-thiolactone induces caspase-independent vascular endothelial cell death with apoptotic features. Apoptosis 5:403-411, 2000
11. Jakubowski H: Protein homocysteinylation: Possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J 13:2277-2283, 1999
12. Liu G, Nellaiappan K, Kagan HM: Irreversible inhibition of lysine oxidase by homocysteine thiolactone and its selenium and oxygen analogues. J Biol Chem 272:32370-32377, 1997
13. Jakubowski H: Calcium-dependent human serum homocysteine thiolactone hydrolase. J Biol Chem 275:3957-3962, 2000
14. Mackness MI, Arrol S, Abbott CA, et al: Protection of low density lipoprotein against oxidative modification by high density lipoprotein associated paraoxonase. Atherosclerosis 104:129-135, 1993
15. Aviram M, Rosenblat M, Bisgaier CL, et al: Paraoxonase inhibits high density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 101:1581-1590, 1998
16. Macknes B, Durrington PN, Mackness MI: Human serum paraoxonase. Gen Pharmacol 31:329-336, 1998
17. Mackness MI, Mackness B, Durrington PN, et al: Paraoxonase biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 7:69-76, 1996
18. Ruiz J, Blanche H, James RW, et al: Gln-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 346:869-872, 1993
19. Jakubowski H, Ambrosius WT, Pratt JH: Genetic determinants of homocysteine thiolactonase activity in humans: Implication for atherosclerosis. FEBS Lett 491:35-39, 2001
20. James WR, Leviev L, Righetti A: Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 101:2252-2257, 2000
21. Chung BH, Segres JP, Ray MJ, et al: Single vertical spin density gradient ultracentrifugation. Methods Enzymol 128:181-209, 1986
22. 2C leukaemic lymphocytes. Biochimie 68:723-730, 1986
23. Hu ML: Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol 233:380-385, 1994
24. Navab M, Hama-Levy S, Van Lenten BJ, et al: Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. Clin Invest 99:2005-2019, 1997
25. Lowry OH, Rosebrough NJ, Farr AL, et al: Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275, 1951
26. Buege A, Aust SD: Microsomal lipid peroxidation. Methods Enzymol 52:302-310, 1973
27. Ferguson E, Hogg N, Antholine WE, et al: Characterization of the adduct formed from the reaction between homocysteine thiolactone and low-density lipoprotein: Antioxidant implications. Free Radic Biol Med 26:968-977, 1999
28. Billecke S, Draganov D, Counsell R, et al: Human serum paraoxonase (pon1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 28:1335-1342, 2000
29. Milochevitch C, Klalil A: Study of the paraoxonase and platelet-activating factor acetylhydrolase activities with aging. Prostaglandins Leukot Essent Fatty Acids 65:241-246, 2001
30. Khalil A, Jay-Gerin JP, Fulop T Jr: Age-related increased susceptibility of high-density lipoproteins (HDL) to in vitro oxidation induced by gamma-radiolysis of water. FEBS Lett 435:153-158, 1998
31. Hop CE, Bakhtiar R: Homocysteine thiolactone and protein homocysteinylation: Mechanistic studies with model peptides and proteins. Rapid Commun Mass Spectrom 16:1049-1053, 2002
32. s by binding phospholipids: Apo A-I stabilizes activity. Arterioscler Thromb Vasc Biol 19:2214-2225, 1999
33. Oda MN, Bielicki JK, Berger T, et al: Cysteine substitution in apolipoprotein AI primary structure modulate paraoxonase activity. Biochemistry 40:1710-1718, 2001
34. Ferretti G, Bacchetti T, Marchionni C, et al: Effect of glycation of high density lipoproteins on their physico-chemical properties and on paraoxonase activity, Acta Diabetologica 38:163-169, 2001
35. Aviram M, Rosenblat M, Billecke S, et al: Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Rad Biol Med 26:892-904, 1999
36. McCully KS, Vezeridis MP: Homocysteine thiolactone in arteriosclerosis and cancer. Res Commun Chem Pathol Pharmacol 59:107-119, 1988
37. Abbott CA, Mackness MI, Kumar S, et al: Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 15:1812-1818, 1995
38. Paragh G, Balla P, Katona E, et al: Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci 252:63-67, 2002
39. Kleemola P, Freese R, Jauhiainen M, et al: Dietary determinants of serum paraoxonase activity in healthy humans. Atherosclerosis 160:425-432, 2002